Active, Not RecruitingPhase 2psilocybin

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Sponsored by Sheppard Pratt Health System

NCT ID
NCT04433858
Target Enrollment
27 participants
Start Date
2021-03-01
Est. Completion
2026-05-01

About This Study

The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

Conditions Studied

Treatment Resistant Depression

Interventions

  • •Psilocybin

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Diagnosis of at least moderate Major Depressive Disorder (MDD)

Exclusion Criteria:

* Comorbidities

Note for CA site: Only Veterans are Eligible

Study Locations (2)

VA Palo Alto Healthcare System/Stanford Medicine
Palo Alto, California, United States
Sheppard Pratt Health System
Baltimore, Maryland, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) | Huxley